| Name | Title | Contact Details |
|---|
Bionest Partners is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A cancer diagnosis is something no one wants to hear. Today, it is often detected late, once it has spread and treatment options are often limited. But cancer is curable if caught in the earlier stages. At Thrive Earlier Detection, our goal is to transform this outlook: to catch cancer earlier, when it can be more effectively treated. We are developing CancerSEEK, a blood-based test that is designed to be affordable and utilized as part of routine medical care to detect multiple types of cancer at earlier stages. Our approach goes beyond a cancer diagnosis. We are developing a platform that will serve as a resource to help patients and their families maneuver the often confusing and overwhelming path that follows a cancer diagnosis.
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
Allergene is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Prevail Therapeutics, we are pioneering innovative therapies that aim to cure neurodegenerative disorders, such as Parkinson`s disease. Our mission is to translate breakthrough advances in human genetics and gene therapy technology into life-changing medicines that slow, stop and reverse the neurodegenerative process. Our novel gene therapies target patients with urgent unmet needs, where there are currently no available therapies to change the progressive course of their diseases. Prevail was formed in 2017, and as an emerging biotechnology company, we are growing rapidly. We are building a team of dedicated, creative and talented individuals who share our passion for serving patients with neurodegenerative diseases. We pride ourselves on following great science, and we value collaboration, integrity and agility. We are based in the Alexandria Center for Life Science in New York City.